β¨ Medicines Consent
1906
NEW ZEALAND GAZETTE
No. 73
Dosage Form: (Vamin 18 Novum component) Solution for injection
Active Ingredient: Soya oil 20%
Dosage Form: (Intralipid component) Emulsion for injection
New Zealand Sponsor: Fresenius Medical Care New Zealand
Manufacturer: Fresenius Kabi AB, Uppsala, Sweden
Product: Kabiven
Active Ingredients: Glucose monohydrate 20.9 equivalent to 19% glucose anhydrous (Glucose component) Solution for injection
Dosage Form:
Alanine 1.6%
Arginine 1.13%
Aspartic acid 0.34%
Calcium chloride dihydrate 0.074%
Glutamic acid 0.56%
Glycine 0.79%
Histidine 0.68%
Isoleucine 0.56%
Leucine 0.79%
Lysine hydrochloride 0.9%
Magnesium sulphate 0.16%
Methionine 0.56%
Phenylalanine 0.79%
Potassium chloride 0.597%
Proline 0.68%
Serine 0.45%
Sodium acetate trihydrate 0.49%
Sodium glycerophosphate 0.54%
Threonine 0.56%
Tryptophan 0.19%
Tyrosine 0.023%
Valine 0.73%
(Vamin 18 Novum component) Solution for injection
Dosage Form: Soya oil 20% (Intralipid component) Emulsion for injection
New Zealand Sponsor: Fresenius Medical Care New Zealand
Manufacturer: Fresenius Kabi AB, Uppsala, Sweden
Dated this 19th day of June 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go4158
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 73
Gazette.govt.nz —
NZ Gazette 2002, No 73
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of New Medicines
(continued from previous page)
π₯ Health & Social Welfare19 June 2002
Medicines Act, New Medicines, Kabiven, Solution for injection, Emulsion for injection, Fresenius Medical Care New Zealand, Fresenius Kabi AB
- G. R. Boyd, Chief Advisor, Safety and Regulation